Comprehensive analysis of known PGx markers in a single assay
The PharmacoScanTM assay offers drug developers a novel tool to understand the variation in genes coding for drug metabolism and transport. Poor pharmacokinetics (PK), pharmarmacodynamics (PD), and adverse drug reactions (ADRs) are a few common issues that make the drug discovery process costly and lengthy. The PharmacoScanTM assay is designed for multiethnic populations and investigates the functional variation in all the key genes involved in the absorption, distribution, metabolism and excretion (ADME). The assay potentially reduces the lengthy timeline and complexities within the drug discovery process.
- 4,627 markers in 1,191 genes of known pharmacogenomic value
- Comprehensive content of known pharmacogenomic value including phase I and phase II enzymes, regulatory and modifier genes, drug target genes, and phase III transporter genes
- Genotyping of highly predictive markers in genes, including GSTM1, CYP1A2, CYP2D6, CYP2B6, CYP2A6, SULT1A1, CYP2C19, and CYP2C9 that are in highly homologous regions
- Copy number variation (CNV) analysis for copy number states ranging from 0 to >3 for important ADME genes
- Star allele and translation tables for key actionable genes
Why partner with RPRD?
RPRD pioneers in pharmacogenomic research and its translation into actionable clinical tests. Our scientific group is the key collaborator of Thermo Fisher Scientific on the content selection for PharmacoScanTM solution and its clinical validation.
Clinical grade accuracy and liability
The PharmacoScanTM assay has been fully validated as a clinical diagnostic test in our CLIA-certified laboratory. World leading healthcare systems2-3 in the US are utlizing our PharmacoScanTM based pre-emptive Whole Pharmacogenomics Scan (WPSTM) to guide clinical decision making. Our clinical grade assay is highly accurate and reliable.
Leveraging decades of genomics and translational research experience
Utilizing PharmacoScanTM and its predecessor DMET, RPRD has been successfully characterizing genomic DNA reference materials for the GeT-RM program4, for use by the PGx community. This collaborative effort is ongoing and supported by the Centers for Disease Control and Prevention (CDC).
In-depth analysis and clinical interpretation
We offer expert customized follow-up analysis of the PGx data we generate. We provide clinical interpretation to decipher the genetic characteristics (pharmacogenetics) that contribute to the risks, such as poor PK, PD, and toxicity associated with the drug discovery process.
CUSTOM ANALYSIS AND INTERPRETATION
RPRD’s experience in precision medicine offers custom analysis and interpretation to translate complex genomics information into clinical insights.
CUSTOM PGX SOLUTION
RPRD’s experience in precision medicine and its CLIA-certified laboratory offer tailored PGx solutions to meet your unique needs.